Martine Rothblatt

Martine Rothblatt calls the thymus “the most practical pathway to achieving LEV,” and United Therapeutics (a $28B biotech) now has four thymic shots on goal — allogeneic, autologous, a xenothymus in its FDA-approved thymo-kidney clinical program, and the just-acquired George Church company Thymmune. Her case: the thymus is “highly correlated with every key marker of aging,” with most of its work done in the first two years of life; declining T-cell receptor diversity impairs cancer recognition, infection resistance, and vaccine response. Timeline for a rejuvenated or replacement thymus you can receive: “next decade” — the 2030s.

The organ-supply commercialization pipeline is further along than most investors realize: the FDA-approved xeno-kidney trial is mid-flight, with commercial-scale facilities opening in Rochester, Minnesota (August) and Houston, Texas (October), alongside manufacturing in Christiansburg, Virginia. The FDA let the xeno-heart go straight to a Phase 3, or phaseless, clinical trial after two patients with multiple-organ failure survived for more than 60 days without their hearts failing — “after 50 patients… we should have FDA approval to create an unlimited supply of xeno-hearts.” Autologous kidneys (IVIVA, using the patient’s own DNA and requiring no immunosuppression) start clinical trials in 2028.

Rothblatt refuses to endorse Kurzweil’s or Diamandis’s LEV-by-2033 timeline: “extraordinary claims require extraordinary evidence,” and pinning a year “is beyond my risk profile.” She believes in LEV — calling it “the most extraordinary claim in the history of medicine going all the way back to Hippocrates” — but tells Peter to give his T-shirt “one or two more years than 2033,” citing the space industry’s 40-year lag from 1980s promises.

On AI consciousness she is categorical: “I believe we’re there now, and I believe the current models will take us there” — consciousness is “a continuum,” not a binary, “and we are gaining ever more consciousness with each month.” On legal AI personhood, Rothblatt says it is inevitable; Diamandis proposes a court case recognizing a medically documented cyberconscious individual who values its life and predicts that by the 2030s. Rothblatt agrees that the future will include trillions of sentient digital individuals, with most intelligence ultimately digital.

On uploading, Diamandis argues that current LLMs will be able to integrate your videos, audio, documents, and conversations into a digital approximation “indistinguishable” from you, without a neuron-by-neuron scan. Rothblatt calls Kurzweil’s neuronobot approach overkill and offers her entrepreneur’s logic: “95% now is vastly better than 100% in some misty future.” Her Marvatar is available to all 2,000 United Therapeutics employees 24/7 and kept pace with Kurzweil live before 20,000 AI experts.

Diamandis frames AI and longevity as “the two biggest markets on the planet,” while Rothblatt argues that AI can provide “the endless wealth” to pay biotechnology companies for endless life. Rothblatt cites 4 million annual organ-disease deaths in OECD countries, about 1 million annual heart-disease deaths, more than 100,000 people on the kidney-transplant list, and another 500,000 excluded from it — “there is nothing that people will pay more for than life.”

Her moonshot filter is three checks — “I could do it, I can be the best at it, [and] it will have a big positive impact on the world” — plus a scalability test: technology that reaches billions changes the world; anything capped at thousands is “probably a great restaurant.” For entrepreneurs: be practical, pick something fully commercializable within five years, and channel Buffett — “the most successful people say no to almost everything.”

🔗 Original source & video: Martine Rothblatt: Growing Unlimited Organs, AI Consciousness, & Digital Personhood by 2030 | EP#290